Vir, Sana gain new modality POC: BioCentury’s Clinical Report

Standout data from Sana’s islet cell therapy and a pair of masked bispecifics from Vir started the year strong on the new modality front. Yet, less encouraging readouts from more established programs that had high investor expectations continued a narrative of clinical disappointments. 

Phase I data from Sana Biotechnology Inc. (NASDAQ:SANA) — the first from its hypoimmune cell therapy platform — raise the prospect of Type I diabetes patients replacing regular insulin injections with a durable cell therapy that’s free of the risks of immunosuppression. The result also builds confidence in the company’s allogeneic T cell program...